1. Home
  2. CMPX vs QURE Comparison

CMPX vs QURE Comparison

Compare CMPX & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$1.91

Market Cap

927.5M

Sector

Health Care

ML Signal

HOLD

Logo uniQure N.V.

QURE

uniQure N.V.

HOLD

Current Price

$22.82

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMPX
QURE
Founded
2014
1998
Country
United States
Netherlands
Employees
N/A
248
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
927.5M
1.1B
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
CMPX
QURE
Price
$1.91
$22.82
Analyst Decision
Strong Buy
Buy
Analyst Count
9
14
Target Price
$14.57
$45.00
AVG Volume (30 Days)
10.8M
1.5M
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.67
EPS
N/A
N/A
Revenue
N/A
$13,107,000.00
Revenue This Year
N/A
$126.12
Revenue Next Year
$934.41
$200.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.61
$8.73
52 Week High
$6.88
$71.50

Technical Indicators

Market Signals
Indicator
CMPX
QURE
Relative Strength Index (RSI) 24.24 68.60
Support Level $1.61 $22.59
Resistance Level $3.63 $25.66
Average True Range (ATR) 0.38 1.47
MACD -0.26 0.53
Stochastic Oscillator 5.04 96.04

Price Performance

Historical Comparison
CMPX
QURE

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

About QURE uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Share on Social Networks: